USA flag logo/image

An Official Website of the United States Government

Development of a prototype system for assaying exocytosis from individual cells

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2011 / SBIR
Agency Tracking Number:
R43MH096650
Solicitation Year:
2011
Solicitation Topic Code:
NIMH
Solicitation Number:
PA08-114
Small Business Information
EXOCYTRONICS, LLC
104 MU LIFE SCIENCES BUSINESS INCUBATOR COLUMBIA, MO 65211-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2011
Title: Development of a prototype system for assaying exocytosis from individual cells
Agency: HHS
Contract: 1R43MH096650-01A1
Award Amount: $671,743.00
 

Abstract:

DESCRIPTION (provided by applicant): Cells secrete hormones and neurotransmitter via exocytosis. Understanding how exocytosis is regulated and how pharmaceuticals and toxins inhibit exocytosis is of broad medical significance. The overall goal of this SBIRproject is to use microfabrication technology to develop a robust and easy-to-use prototype device that can assay release of transmitter from individual cells 10- 100 fold faster and cheaper than current approaches and thereby greatly accelerate the paceof biomedical research. In addition, the devices will provide entirely novel capabilities such as the ability to simultaneously image a fluorescently labeled vesicle while measuring release from the same vesicle with an underlying transparent electrochemical electrode. The Specific Aim is to develop and test a prototype transparent multi-well electrochemical-electrode array device. Each of the wells will be a separate experimental chamber and will contain an array of electrochemical electrodes on the bottom. Individual cells will be docked to each electrode through the use of cell-sized microwells and patterning of cell-adhesion molecules. The electrodes will be transparent and patterned on a thin glass substrate to allow simultaneous high-resolution opticaland electrochemical measurements. The electrode arrays will be multiplexed using a proprietary approach to simplify the number of connections required to an external amplifier. The specific milestone for Phase 1 is to record quantal exocytosis from at least 100 cells within one hour using a single multi-well device. Achieving this milestone will demonstrate that the prototype device can acquire data ~10-fold faster than the current method using carbon-fiber microelectrodes, and thus will establish that radical improvements in throughput can be achieved in a practical platform. Potential markets for the devices include the biomedical research community, the pharmaceutical industry to carry out high-throughput screening of drugs that target exocytosis, a clinical market to perform automated assays of botulism without the use of laboratory animals and a defense / homeland security market to detect neurotoxin bioweapons with cell-based biosensors. Exocytronics LLC will consult potential academic users / customers to provide feedback on device design, will obtain marketing advice from an experienced corporate partner and will obtain entrepreneurial support while housed in the MU Life Sciences Business Incubator. PUBLIC HEALTH RELEVANCE: The goal of this project is to develop a robust and easy-to-use prototype device that can assay secretion of signaling molecules from individual cells 10- 100 fold faster and cheaper than current approaches. The devices will greatly accelerate the pace of medical research tounderstand how pharmaceuticals alter cell secretion. Other applications include automated assays of food poisoning without the use of laboratory animals and improved detection of neurotoxin bioweapons.

Principal Investigator:

Xin A. Liu
573-445-3068
liuxin@missouri.edu

Business Contact:

Kevin Gillis
573-445-3068
GillisK@exocytronics.com
Small Business Information at Submission:

EXOCYTRONICS, LLC
104 MU LIFE SCIENCES BUSINESS INCUBATOR COLUMBIA, MO 65211-

EIN/Tax ID: 127255683
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No